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Abstract
AIM: To investigate the biological impacts of “hot-spot”
mutations on genotype B and C HBV X proteins (HBx).
METHODS: Five types of “hot-spot” mutations of genotype
B or C HBV X genes, which sequentially lead to the amino
acid substitutions of HBx as I127T, F132Y, K130M+V131I,
I127T+K130M+V131I, or K130M+V131I+F132Y, respectively,
were generated by means of site-directed mutagenesis.
To evaluate the anti-proliferative effects, HBx or related
mutants’ expression vectors were transfected separately
to the Chang cells by lipofectamine, and the cells were
cultured in hygromycin selective medium for 14 d, drug-
resistant colonies were fixed with cold methanol, stained
with Giemsa dyes and scored (increase of the colonies
indicated the reduction of the anti-proliferation activity,
and vice versa). Different types of HBx expression vectors
were co-transfected separately with the reporter plasmid
pCMVβ to Chang cells, which were lysed 48 h post-
transfection and the intra-cellular β-galactosidase
activities were monitored (increase of the β-galactosidase
activities indicated the reduction of the transactivation
activity, and vice versa). All data obtained were
calculated by paired-samples t-test.
RESULTS: As compared to standard genotype B HBx,
mutants of I127T and I127T+K130M+V131I showed higher
transactivation and anti-proliferative activities, while the
mutants of F132Y, K130M+V131I, and K130M+V131I+F132Y
showed lower activities. As compared to standard genotype
C HBx, I127T mutant showed higher transactivation
activity, while the other four types of mutants showed
no differences. With regard to anti-proliferative activity,
compared to standard genotype C HBx, F132Y and K130M+
V131I mutants showed lower activities, and K130M+V131I
+F132Y mutant, on the other hand, showed higher activity,
while the mutants of I127T and I127T+K130M+V131I
showed no differences.
CONCLUSION: “Hot-spot” mutations affect the anti-
proliferation and transactivation activities of genotype
B and/or C HBx, and the biological impacts of most
“hot-spot” mutations on HBx are genotype B and C
differentiated.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
HBV belongs to the hepadnaviridae family, which has a
double-stranded DNA genome with a single-stranded gap.
The genome of HBV encodes four kinds of proteins
including the envelope protein (S/Pre-S), the core protein
(C/pre-C), the polymerase (P), and the X protein (HBx).
HBx is a multi-functional transcriptional transactivator[1]
and has been shown to be crucial in the pathogenesis of
HBV-related diseases[2].
Based on an intergroup divergence of 8% or more in
the complete or partial nucleotide sequences, HBV can be
classified presently into eight genotypes[3,4], termed A-H, in
which B and C genotypes are prevalent in East Asia including
China[5]. Recent studies[6,7] revealed that the infection of
genotype B or C HBV brought about quite different clinical
manifestations and liver histological changes, yet the exact
mechanisms involved remain largely obscure. Considering
the important role HBx plays in the pathogenesis of HBV,
it is reasonable to speculate that the clinical and histological
differences of the infection of genotype B and C HBV
may be partially related with the functional differentiations
between these two genotypes of HBx due to the genetic
variability.
Genetic variability[8] of HBx includes both of the
genotype-specific variations and the mutations emerged
during chronic infection. We had shown in our previous
study[9] that there were 16 amino acid genotype-specific
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variations between genotype B and C HBx, and the
biological functions including transactivation activities and
anti-proliferation capacities were different between these two
HBx genotypes. It was also demonstrated that during chronic
infection, genotype B and C HBx shared the same “hot-spot”
mutations in the amino acid positions of 127, 130, 131,
and 132[10], we wondered whether these “hot-spot” mutations
effected HBx, and more importantly, whether the influences
of the same type of mutation on HBx showed genotype B
or C specificity. To address these issues, we constructed
HBx mutants of each genotype (B or C) with the same
“hot-spot” mutations, and comparatively analyzed their
differences in biological functions.
MATERIALS AND METHODS
Plasmids
pcDNA3.1-XB and pcDNA3.1-XC were recombinant
pcDNA3.1/Hygro(-) (Invitrogen, USA) vectors harboring
either genotype B or genotype C HBV X gene with
conserved sequences (the amino acid alignment of  these
two genotypes of HBx is shown in Figure 1) and could
express HBx in transfected Chang cells, as detected by
immunohistochemistry.
Generation of genotype B or C HBV X mutants with “hot-
spot” mutations
pcDNA3.1-XB or pcDNA3.1-XC was used as the template
and the mutagenesis was carried out using GeneTailor
site-directed mutagenesis system (Invitrogen, USA) following
the manufacturer’s instructions. In brief, 200 ng of
pcDNA3.1-XB or pcDNA3.1-XC DNA was methylated
by 8 U methylase in a total volume of 32 µL, and 2 µL of
methylated DNA was used as the template for PCR using
paired primers (reverse primer R was used together with
one of the forward primers F1-F5 to generate nucleotide
mutation, sequentially resulting in amino acid substitution)
(Table 1). After amplification, 5 µL of  PCR product was
used to transform E. coli DH5α-T1, and transformants were
screened by growth on bacterial culture plates with ampicillin
for selection. All mutants were sequenced to confirm the
correctness of the induced mutations.
Cell culture and transfection
The human liver cell line, CCL13 (Chang cells) was cultured
in Dulbecco’s modified Eagle minimal essential medium
with penicillin (100 U/mL) and streptomycin (100 µg/mL),
supplemented with 10% fetal calf serum. Recombinant
plasmid DNA was extracted and purified with Qiagen
maxiprep kits, and used to transfect Chang cells in 60-mm
plates or six-well plates by lipofectamine 2000. Duplicate
plates/wells were used for all samples. Empty vector
pcDNA3.1/Hygro(-) was used as a mock transfection
control.
Colony formation assay
Chang cells (3×105) in six-well plates were transfected with
2.5 µg of  HBx constructs or empty vector. Forty-eight hours
after transfection, the cells were subcultured at a ratio of
1:3, and cultured in 200 µg/mL hygromycin (Roche,
Germany) selective medium for 14 d. Drug-resistant colonies
were fixed with cold methanol, stained with Giemsa, and
then scored.
β-galactosidase test
Two micrograms of  HBx constructs and 2.0 µg reporter
pCMVβ plasmids (Promega, USA) were co-transfected into
Chang cells in 60-mm plates (5×105 cells per plate). Cells
were harvested and lysed at 48 h post-transfection. After
protein normalization by the Bradford assay (Bio-Rad
Laboratories, Hercules, CA, USA), equal amounts of protein
(30 ng) were used for β-galactosidase assay following the
manufacturer’s instructions.
Statistical analysis was performed using a paired t-test.
P<0.05 was taken as significant.
RESULTS
Generation of genotype B or C HBx mutants
Mutations at HBV nucleotides 1 753, 1 762, 1 764, and
1 768 resulted in amino acid substitution of HBx at positions
127, 130, 131, and 132, respectively. In this study, nucleotide
mutations were generated in each genotype of HBx with
five types of combinations as 1 753T C, 1 762A T+1 764G
A, 1 753T C+1 762A T+1 764G A, 1 762A T+1 764G A
Table 1  Sequences and related applications of the primers used for site-directed mutagenesis and nomenclature of HBx mutants
        Applications
Primers       Sequences (5’ 3’) Nomenclature of the HBx mutants
   Nucleotide mutation2 Amino acid substitution3
R       CTCCTCCCCCAACTCTTCCCACTCAGTAAAC
F1       GAAGAGTTGGGGGAGGAGAC1    1 753T C I127T XB/XC-127
     TAGGTTAAAGGTC
F2       GAAGAGTTGGGGGAGGAGACTAGGTTA    1 753T C+1 762A T+1 764G A I127T+K130M+V131I XB/XC-127-130-131
     ATGATCTTTGTACTAGG
F3       GAAGAGTTGGGGGAGGAGATTAGGTTA    1 762A T+1 764G A K130M+V131I XB/XC-130-131
     ATGATCTTTGTACTAGG
F4       GAAGAGTTGGGGGAGGAGATTAGGTTA    1 762A T+1 764G A+1 768T A K130M+V131I+F132Y XB/XC-130-131-132
     ATGATCTATGTACTAGGAGGC
F5       GAAGAGTTGGGGGAGGAGATTAGGTTA    1 768T A F132Y XB/XC-132
     AAGGTCTATGTACTAGGAGGC
1Mutated nucleotides are shown as underlined; 21 753, 1 762, 1 764, 1 768 indicate the positions of mutated nucleotides in HBV genome; 3127, 130, 131, 132 are positions
of substituted amino acids in HBx.
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+1 768T A and 1 768T A, which sequentially resulted in
amino acid substitutions as I127T, K130M+V131I,
I127T+K130M+V131I, K130M+V131I+F132Y, and
F132Y, respectively (Table 1 and Figure 1). The X mutants
were named according to their genotype belongings (B or
C) and the position of the substituted amino acids, for
example, XB-127 for I127T mutant of genotype B HBx,
while XC-127 for I127T mutant of genotype C HBx.
Figure 1  There were 16 amino acid variations between genotype B and C
HBx, which were located at amino acid positions 5, 30, 31, 34, 36, 39, 40, 42,
43, 44, 47, 87, 88, 116, 118, and 119, respectively. Four boxed amino acids,
located at the positions of 127, 130, 131, 132, respectively, were to be substituted
by site-directed mutagenesis.
Anti-proliferation activities of genotype B or C HBx mutants
To study the anti-proliferation activities of  HBx mutants,
we performed colony formation assay[11], in which the
increasing anti-proliferation activities should be paralleled
with the reduction of cell colonies, and vice versa. Chang
cells were transfected separately with parental vector
pcDNA3.1/Hygro(-) or recombinant vectors harboring
different types of HBx; cells were subcultured in hygromycin
selective medium 48 h post-transfection, and the drug-resistant
colonies formed 14 d later were stained with Giemsa and
scored. The results showed that, as compared with XB
(standard genotype B HBx), expression of mutants XB-127
and XB-127-130-131 caused the reduction in the number
of colonies, and expression of mutants XB-132, XB-130-131,
or XB-130-131-132 caused the elevation (Figure 2). As for
genotype C HBx, expression of mutant XC-130-131-132
caused the sharp reduction of colonies to zero, and mutants
of XC-132 and XC-130-131, on the other hand, caused
the elevation in the number of colonies as compared
with XC (standard genotype C HBx), while XC-127 and
XC-127-130-131 showed no differences from XC (Figure 3).
It indicated that effects of three types of “hot spot”
mutations, i.e., I127T, I127T+K130M+V131I, and
K130M+V131I+F132Y, on anti-proliferation of HBx were
             5                15             25              35             45              55
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Figure 3  Chang cells were transfected by genotype C X gene expression
vectors and screened by hygromycin, the drug-resistant colonies formed 14 d
post-transfection were fixed by cold methanol, stained with Giemsa (A) and
scored (B). The results are shown as mean±SD of six separate experiments.
Figure 2  Chang cells were transfected by genotype B X gene expression
vectors and screened by hygromycin, the drug-resistant colonies formed 14 d
post-transfection were fixed by cold methanol, stained with Giemsa (A) and
counted (B). The results are shown as mean±SD of six separate experiments.
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genotype B and C differentiated. In addition, it was also
demonstrated that all HBx caused dramatic reduction of
colonies as compared with the empty vector pcDNA3.1/
Hygro(-), irrespective of genotypes (B or C) or the types
(the standard or the mutants), indicating the retaining of
anti-proliferation activities of all HBx.
Transactivation activities of genotype B or C HBx mutants
It was reported previously that HBx could transactivate the
CMV immediate early promoter[12], so plasmid pCMVβ
containing the CMV immediate early promoter and
expressing β-galactosidase was used as the indicator to
evaluate the transactivation activities of HBx mutants. In
our study, pCMVβ was co-transfected with an HBx
construct to Chang cells, which were lysed 48 h post
transfection, and intra-cellular β-galactosidase activities were
monitored. The results showed that, as for genotype B HBx,
expression of mutants XB-127 and XB-127-130-131
induced increase in β-galactosidase activities as compared
with XB, and three other mutants, i.e., XB-132, XB-130-131,
and XB-130-131-132 induced decreased activities (Figure 4A
and Table 2), as for genotype C HBx, XC-127 induced the
increase in β-galactosidase activities as compared with XC,
while the other four types of mutants showed no differences
(Figure 4B and Table 2). The results revealed that effects
of four types of “hot spot” mutations, i.e., I127T+K130M+
V131I, K130M+V131I, K130M+V131I+F132Y, and
F132Y, on transactivation of HBx were genotype B and C
differentiated. In addition, the results also showed that
expression of HBx, irrespective of genotypes (B or C) or
the mutant types, induced the increase in intra-cellular
β-galactosidase activities as compared with the empty vector
pcDNA3.1/Hygro(-), indicating the retaining of transactivation
activities of all HBx.
DISCUSSION
There are increasing evidences that the clinical manifestations,
the long-term prognosis, the liver histological changes, and
the response to treatment of interferon and nucleosidic
inhibitors may differ depending on which genotype of HBV
the patient has been infected with[13]. In Taiwan, where the
genotypes of HBV were predominantly B and C, genotype
C is associated with more severe liver disease and genotype
B is associated with the development of hepatocellular
carcinoma (HCC) in young non-cirrhotic patients[6]. In
contrast, genotype B has a relatively good prognosis in Japan
and China and is rarely associated with the development
of HCC[7]. However, the impact of genotypes on HBV
pathogenesis remains largely obscure.
HBx is a promiscuous activator[1] and considered to be
of importance in the pathogenesis of HBV, it can indirectly
activate miscellaneous viral and cellular genes[14], induce or
block apoptosis of the infected cells[15,16], and induce HCC
in certain lines of  transgenic mice[17,18]. We demonstrated
previously that there were 16 amino acid differences
between standard genotype B and C HBx, and the activities
including transactivation and anti-proliferation were different
between these two genotypes of HBx. These results
indicated that the B, C genotype-specific structural and
functional differentiations of HBx may partially contribute
to the different clinical outcomes and histological changes
of the infection with genotype B or C HBV.
In addition to the genotype-specific variations, both of
B and C genotypes of HBx also showed the same gene
mutations within their coding regions (nt1 376-1 840), i.e.,
nt1 753T C, nt1 762A T, nt1 764G A, and nt1 768T A, which
accordingly led to the amino acid variations as I127T,
K130M, V131I, and F132Y. These “hot-spot” mutations
Figure 4  Chang cells were co-transfected by pCMVβ together with the X gene
or related mutants with genotype B (A) or genotype C (B). Forty-eight hours
post-transfection, the cells were lysed and the intracellular β-galactosidase
activities were monitored after protein normalization. The results are shown as
mean±SD of six separate experiments.
Table 2 Intracellular β-galactosidase activities of transfected Chang
cells by pCMVβ and X gene expression vectors
DNA transfected β-galactosidase activities1                    P2  P3
pcDNA3.1/Hygro(–)                0.147±0.039 -   -
XB                0.593±0.051               <0.01   -
XB-127                0.666±0.054               <0.01          <0.05
XB-132                0.492±0.052               <0.01          <0.01
XB-130-131                0.477±0.065               <0.01          <0.01
XB-127-130-131                0.680±0.090               <0.01          <0.05
XB-130-131-132                0.472±0.081               <0.01          <0.05
XC                0.505±0.064               <0.01   -
XC-127                0.641±0.044               <0.01          <0.01
XC-132                0.571±0.104               <0.01          >0.05
XC-130-131                0.459±0.065               <0.01          >0.05
XB-127-130-131                0.457±0.067               <0.01          >0.05
XB-130-131-132                0.646±0.177               <0.01          >0.05
1All data are expressed as mean±SD of six separate experiments; 2Paired-samples
t-test between pcDNA3.1/Hygro(–) and all HBx; 3Paired-samples t-test between
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emerged due to the error-prone reverse transcriptase activity
of  HBV polymerase[19] and the long-term virus-host
interaction, and occurred mainly during chronic infection
including different clinical stages of chronic hepatitis[20] and
HBV-associated HCC as well[21]. In fact, these “hot-spot”
mutations appeared predominantly in five types: I127T,
F132Y, K130M+V131I, I127T+K130M+V131I, or
K130M+V131I+F132Y. Our results demonstrated that these
mutations affected the anti-proliferation and transactivation
activities of genotype B and/or C HBx, and more importantly,
the impacts of most types of the “hot-spot” mutations on
HBx were genotype B and C differentiated, i.e., as concerning
the anti-proliferation activities, impacts of HBx mutants of
I127T, I127T+K130M+V131I, and K130M+V131I+F132Y
showed genotype B and C differentiated, and regarding
the transactivation activities, impacts of mutants of
I127T+K130M+V131I, K130M+V131I, K130M+V131I
+F132Y, and F132Y showed genotype B and C differentiated
(Table 3).
It was also revealed that all HBx mutants, irrespective
of genotypes or mutant types, retained their biological
functions. It may be therefore concluded that the effects
of the mutations on HBx was relatively mild and was in
strong contrast to the distal COOH-terminal deletion
mutants isolated from the integrated chromosomes of HCC
tissues, which completely abrogated the transactivation or
anti-proliferation activities[22,23]. In addition, it was previously
reported that the transactivation activities of HBx are often
linked to anti-proliferation function[24]. Our results strikingly
showed that the linkage of these two activities only occurred
in genotype B HBx, in which the increasing activation
activities of HBx mutants were coupled with the enhanced
anti-proliferation activities, and vice versa, while it seemed
that the activities of anti-proliferation and transactivation
were completely separated in genotype C HBx (Table 3).
Therefore, it was concluded that association of transactivation
with anti-proliferation activities was a common feature of
HBx with genotype B rather than genotype C.
There is no indisputable evidence showing that the
transactivation activity of HBx contributes to liver disease.
However, reduction of the anti-proliferation effect may
endow a growth advantage on cells containing these
particular HBx mutants, while increase of anti-proliferation
effects will lead to cell disruption and hence accelerate
intracellular spread of HBV[25]. So in this point, any
functional changes of anti-proliferation are pathogenic.
In summary, “hot-spot” mutations affect the anti-
proliferation and transactivation activities of genotype B
and/or C HBx, and the biological impacts of most “hot-
spot” mutations on HBx are genotype B and C differentiated.
Together with our previous findings demonstrating the
different biological functions between genotype B and C
HBx[9,26], we conclude that genetic variability results in
functional differentiations between genotype B and C HBx.
Nevertheless, considering the sophisticated mechanism of
HBV pathogenesis[27], whether these genotype B and C
specific functional differentiations of HBx are responsible
for the different clinical outcomes and liver histological
changes between two genotypes of HBV, and more
importantly, the exact mechanisms involved await further
studies.
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